- Home
- BTAI vs CIF Comparison
BTAI vs CIF Comparison
Compare BTAI & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTAI | CIF |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 29.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTAI | CIF |
|---|---|---|
| Price | $1.25 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 597.0K | 50.4K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | ★ 75.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $197.82 | N/A |
| Revenue Next Year | $910.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.57 |
| 52 Week High | $8.08 | $1.82 |
Technical Indicators
Market Signals| Indicator | BTAI | CIF |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 47.92 |
| Support Level | $1.05 | $1.57 |
| Resistance Level | $1.26 | $1.73 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 47.83 | 75.00 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.